Boulad F, Bromley M, Black P, Heller G, Sarafoglou K, Gillio A, Papadopoulos E, Sklar C
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Bone Marrow Transplant. 1995 Jan;15(1):71-6.
Thyroid dysfunction has been reported following single dose and fractionated radiation in the context of bone marrow transplantation (BMT). Limited data are available regarding this complication following hyperfractionated radiation. We undertook a retrospective analysis of thyroid function in 150 patients who received BMT at our institution, and who were alive and disease-free for at least 1 year after transplant. There were 100 pediatric patients and 50 adult patients, with a median follow-up of 6.2 years for the whole group. These patients had acute (n = 91) or chronic leukemias (n = 36), severe aplastic anemia (n = 18) or immunodeficiency disorders (n = 5). The majority of the patients received radiation-based cytoreductive regimens including 129 patients who received hyperfractionated total body irradiation (TBI) to a total dose of 1375 cGy or 1500 cGy and 10 patients who received total lymphoid irradiation (TLI) to a total dose of 600 cGy. Twenty two patients of the cohort of 150 patients (14.7%) and 21 of the 139 patients (15.1%) who received hyperfractionated radiation were found to have developed hypothyroidism, 11-88 months after transplant (median 49 months). Eight patients had received 1375 cGy and 12 patients 1500 cGy TBI, while one patient was treated with 600 cGy TLI and one patient was treated with chemotherapy only (busulfan and cyclophosphamide). Three patients had primary thyroid failure with an elevated TSH and a low T4 index, while 19 patients had compensated hypothyroidism with an elevated TSH but a normal T4 index. Six of eight patients with untreated compensated hypothyroidism recovered spontaneously.(ABSTRACT TRUNCATED AT 250 WORDS)
在骨髓移植(BMT)背景下,单次剂量和分次放疗后已报告出现甲状腺功能障碍。关于超分割放疗后这种并发症的数据有限。我们对在本机构接受BMT且移植后存活且无病至少1年的150例患者的甲状腺功能进行了回顾性分析。其中有100例儿科患者和50例成年患者,全组中位随访时间为6.2年。这些患者患有急性(n = 91)或慢性白血病(n = 36)、严重再生障碍性贫血(n = 18)或免疫缺陷疾病(n = 5)。大多数患者接受了基于放疗的细胞减灭方案,包括129例接受超分割全身照射(TBI)、总剂量为1375 cGy或1500 cGy的患者,以及10例接受总淋巴照射(TLI)、总剂量为600 cGy的患者。在150例患者队列中,22例(14.7%)以及接受超分割放疗的139例患者中的21例(15.1%)在移植后11 - 88个月(中位49个月)出现了甲状腺功能减退。8例患者接受了1375 cGy的TBI,12例接受了1500 cGy的TBI,1例患者接受了600 cGy的TLI,1例患者仅接受了化疗(白消安和环磷酰胺)。3例患者出现原发性甲状腺功能减退,促甲状腺激素(TSH)升高且甲状腺素(T4)指数降低,而19例患者为代偿性甲状腺功能减退,TSH升高但T4指数正常。8例未经治疗的代偿性甲状腺功能减退患者中有6例自发恢复。(摘要截断于250字)